Does the number of bifunctional chelators conjugated to a mAb affect the biological activity of its radio-labeled counterpart? Discussion using the example of mAb …
U Karczmarczyk, A Sawicka, P Garnuszek… - Journal of Medicinal …, 2022 - ACS Publications
There has been considerable interest in developing a monoclonal antibody (mAb) against-
CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non …
CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non …
Production and clinical applications of radiopharmaceuticals and medical radioisotopes in Iran
During past 3 decades, nuclear medicine has flourished as vibrant and independent
medical specialty in Iran. Since that time, more than 200 nuclear physicians have been …
medical specialty in Iran. Since that time, more than 200 nuclear physicians have been …
[HTML][HTML] Nano Yttrium-90 and Rhenium-188 production through medium medical cyclotron and research reactor for therapeutic usages: a Simulation study
A Khorshidi - Nuclear Engineering and Technology, 2023 - Elsevier
The main goal of the coordinated project development of therapeutic radiopharmaceuticals
of Y-90 and Re-188 is to exploit advancements in radionuclide production technology. Here …
of Y-90 and Re-188 is to exploit advancements in radionuclide production technology. Here …
Synthesis and Preclinical Evaluation of 177Lu-CHX-A”-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma
M Kameswaran, U Pandey, C Dhakan… - Cancer Biotherapy …, 2015 - liebertpub.com
Introduction: Radioimmunotherapy is a feasible treatment modality for B-cell lymphomas
expressing CD20 antigen. Tagging of anti-CD20 monoclonal antibody with a β− emitter will …
expressing CD20 antigen. Tagging of anti-CD20 monoclonal antibody with a β− emitter will …
Standardization of Procedures for the Preparation of 177Lu-and 90Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
W Wojdowska, U Karczmarczyk… - Current …, 2015 - ingentaconnect.com
Rituximab when radiolabelled with 177Lu or 90Y has been investigated for the treatment of
patients with Non-Hodgkin's Lymphoma. In this study, we optimized the preparation of …
patients with Non-Hodgkin's Lymphoma. In this study, we optimized the preparation of …
[PDF][PDF] Formulation and characterization of “Ready to Use” 1B4M-DTPA-rituximab for Lu-177 labeling
D Gjorgieva Ackova, K Smilkov… - World Journal of …, 2014 - eprints.ugd.edu.mk
Investigations for NHL treatment are oriented towards radiolabelled therapeutics. This
research focuses on formulation and characterization of a new, ready to label …
research focuses on formulation and characterization of a new, ready to label …
Preclinical Characterization of the Radioimmunoconjugate 111In or 90Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a …
Y Funase, E Nakamura, M Kajita, Y Saito… - Journal of Nuclear …, 2021 - Soc Nuclear Med
P-cadherin is overexpressed in various cancers and can be a target for
radioimmunotherapy. We investigated the preclinical pharmacokinetics and pharmacology …
radioimmunotherapy. We investigated the preclinical pharmacokinetics and pharmacology …
Preliminary in vitro comparison of 111In and 131I labeled nimotuzumabs
Z Liao, F Li, Y Tang, W Liu, J Gao, T Lan, J Yang… - … of Radioanalytical and …, 2021 - Springer
The anti-tumor cell proliferative effect of [111 In] In-DOTA-nimotuzumab and [131 I] I-ATE-
nimotuzumab was systematically investigated. Both indium-111 and iodine-131 were …
nimotuzumab was systematically investigated. Both indium-111 and iodine-131 were …
Matching chelators to radiometals for positron emission tomography imaging-guided targeted drug delivery
H Deng, H Wang, Z Li - Current Drug Targets, 2015 - ingentaconnect.com
Positron emission tomography (PET) is a functional imaging modality that measures
pathophysiology status of disease noninvasively, and has become a key component for …
pathophysiology status of disease noninvasively, and has become a key component for …
Impact of DOTA-Chelators on the Antitumor Activity of 177Lu-DOTA-Rituximab Preparations in Lymphoma Tumor-Bearing Mice
W Wojdowska, U Karczmarczyk, L Balog… - Cancer Biotherapy & …, 2020 - liebertpub.com
Background: This work aimed to evaluate the influence of two chelators: DOTA (SCN) and
DOTA (NHS) on radioimmunotherapy using 177Lu-DOTA-Rituximab preparations in murine …
DOTA (NHS) on radioimmunotherapy using 177Lu-DOTA-Rituximab preparations in murine …